Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 11/20 | 0.61 |
| ▸ | PPARG | P37231 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL541938 | 1.00 | CASR (0.61) | CASRPPARGSMN1; SMN2PDE4APDE4B | |
| SCHEMBL541461 | 0.91 | CASR (0.47) | CASRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL541235 | 0.91 | CASR (0.47) | CASRSMN1; SMN2MEN1KMT2A | |
| SCHEMBL3946612 | 0.90 | CASR (0.49) | CASRPPARGSMN1; SMN2PDE4APDE4B | |
| SCHEMBL542073 | 0.90 | CASR (0.49) | CASRPPARGSMN1; SMN2PDE4APDE4B | |
| SCHEMBL541602 | 0.87 | CASR (0.55) | CASRPPARGSMN1; SMN2MEN1KMT2A | |
| SCHEMBL541603 | 0.87 | CASR (0.55) | CASRPPARGSMN1; SMN2MEN1KMT2A | |
| SCHEMBL541858 | 0.86 | CASR (0.46) | CASRPPARGPTGES | |
| SCHEMBL541327 | 0.86 | CASR (0.46) | CASRPPARGPTGES | |
| SCHEMBL541529 | 0.84 | CASR (0.43) | CASRPPARGSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1509518-B1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC (US) | 2012-02-08 | — | — | EP | claimed |
| US-7176322-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-02-13 | — | — | US | claimed |
| EP-1509518-B1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC (US) | 2012-02-08 | — | — | EP | disclosed |
| EP-1509518-B1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC (US) | 2012-02-08 | — | — | EP | disclosed |
| US-7176322-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176322-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-7176322-B2 | Calcium receptor modulating agents | AMGEN INC. (US) | 2007-02-13 | — | — | US | disclosed |
| US-20040077619-A1 | Calcium receptor modulating agents | AMGEN INC. | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077619-A1 | Calcium receptor modulating agents | PTH1R, CASR, CALCR | CASR 2/4885PPARG 1359/4885SMN1; SMN2 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.